Delivering Clinically Relevant Gene Expression Profiling for Physicians and their Cancer Patients


As an innovative molecular cancer diagnostics company, Agendia leverages its knowledge and expertise in the application of clinically useful gene expression profiling to facilitate diagnosis, prognosis and cancer therapeutics development. With a robust pipeline of new cancer profiles in development, Agendia continues to be a leader in personalized medicine.


Future Launch: ColoPrint® Gene Expression Profile for Colon Cancer Recurrence

ColoPrint is a microarray-based gene expression profile for predicting the recurrence of stage II and III colon cancer patients. Currently in the final stage of development, the combination of this profile and selected clinical variables could prove even more powerful and accurate in identifying high risk patients for clinical management.

 

Launched 2010: BluePrint™ Molecular Subtyping Profile for Breast Cancer Intrinsic Subtypes

The BluePrint Molecular Subtyping Profile is an 80-gene expression profile for the classification of breast cancer tumors into Basal-type, Luminal-type and ERBB2-type subclasses. Research suggests that breast cancer patients with these molecular subtypes have different prognoses and may respond better to specific therapies.

 
Launched 2009: Bio-Repository Services

Agendia understands that each tumor sample contains vital information which not only serves the patient today, but also provides a foundation for future answers to medical questions. The NCI recommends that all bio-repositories use the RNALater or RNARetain® room temperature, molecular fixative to maintain the highest quality genomic information during transportation.  Agendia offers cryogenic bio-repository tumor banking services for all samples taken either from a core needle or surgical biopsy.


Launched 2009: TheraPrint® – Drug Therapy Panel


TheraPrint is a microarray-based gene expression panel of 56 genes that have been identified as potential targets for prognosis and therapeutic response to a variety of therapies. Although these genes are still in a research phase, in the future they may hold the key to a greater level of personalized prognosis and therapy for breast cancer patients.


Launched 2008: TargetPrint® for Estrogen Receptor, Progesterone Receptor & HER2/neu Status


TargetPrint is a microarray-based gene expression assay which offers a quantitative assessment of the patient’s level of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu gene within her breast cancer tumor.


Launched 2004: MammaPrint® Gene Expression Profile for Breast Cancer Recurrence


MammaPrint is the first and only FDA-cleared IVDMIA gene expression breast cancer assay. This unique 70-gene signature provides physicians with the unprecedented ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery. MammaPrint interrogates the 70 critical genes that provide a definitive gene expression signature and stratifies patients into two distinct groups – low risk or high risk of distant recurrence. With MammaPrint, there are no intermediate results.
 




Agendia Milestone Chart
Click to enlarge image